First author Hamilton Oh, now at Icahn School of Medicine at Mt. Sinai, New York, and colleagues identified these potential markers during a proteomics analysis of CSF from 3,397 participants in six ...

Like lecanemab before it, donanemab’s path to market has been slow and rocky. In the U.S., the antibody received Food and ...

The scientists concluded that while the two markers perform similarly, they yield complementary information, and sequential ...

The first evidence that removing amyloid plaques may delay Alzheimer’s symptoms has now been published. In The Lancet Neurology on March 19, scientists led by Randall Bateman at Washington University ...

Eight years ago, people were amazed by the first high-resolution glimpse into the core of tau fibrils extracted from the brain of a person who had had Alzheimer’s disease. Since those iconic ...

TgF344-AD rats express human APP with the Swedish mutation and human PSEN1 with the Δ exon 9 mutation. Both transgenes are driven by the mouse prion promoter (Cohen et al., 2013). Compared with levels ...

I am consultant for Janssen pharmaceutica, Remynd NV, Eisai and other companies ...

I have a business degree focusing on healthcare.